TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34140107
Drug: Triglyceride levels
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triglyceride levels ≥150 mg/dl
Study: 34140212
Drug: Hydrocortisone replacement
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone replacement and/or stress dosing during illness
Study: 34140212
Drug: ACTH low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ACTH low-dose stimulation test
Study: 34140248
Drug: Onalespib plus
Normalized name: Onalespib
DrugBank: Onalespib (DB06306)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onalespib plus erlotinib (erlotinib 150 mg orally every morning and onalespib 120 mg/m)
Study: 34140403
Drug: APX005M (0.03,
Approvals — FDA: no, EMA: no, PMDA: no
Description: APX005M (0.03, 0.1, or 0.3 mg/kg i.v.) with cabiralizumab and nivolumab
Study: 34140403
Drug: APX005M (0.03,
Approvals — FDA: no, EMA: no, PMDA: no
Description: APX005M (0.03, 0.1, or 0.3 mg/kg i.v.) with cabiralizumab without nivolumab
Study: 34140482
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of osimertinib and dacomitinib
Study: 34140482
Drug: Optimal dosing
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal dosing schedule for osimertinib and dacomitinib
Study: 34140638
Drug: CGM097 10-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGM097 10-400 mg 3qw
Study: 34140638
Drug: CGM097 300-700
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGM097 300-700 mg 3qw 2 weeks on/1 week off
Study: 34142595
Drug: Enhanced daycare
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced daycare of Traditional Chinese Medicine (TCM)
Study: 34143416
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg eplerenone once daily
Study: 34143998
Drug: Fexinidazole 1800
Normalized name: fexinidazole
DrugBank: Fexinidazole (DB12265)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexinidazole 1800 mg once per day on days 1-4, then 1200 mg on days 5-10
Study: 34145677
Drug: 30-g FMT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-g FMT
Study: 34145677
Drug: 60-g FMT
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60-g FMT
Study: 34145979
Drug: Mobocertinib (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobocertinib (20 mg) with itraconazole (200 mg once daily)
Study: 34145979
Drug: Mobocertinib (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobocertinib (160 mg) with rifampin (600 mg once daily)
Study: 34146238
Drug: Insulin-only configuration
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-only configuration of the iLet
Study: 34146644
Drug: Oral metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral metronidazole treatment for bacterial vaginosis
Study: 34146644
Drug: Healthy women
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy women (no treatment mentioned)
Study: 34147313
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg, intravenously, every 3 weeks for 3 courses)
Study: 34149587
Drug: Robotic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic Therapy (RT)
Study: 34150661
Drug: Temporary ovarian
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temporary ovarian suppression with gonadotropin-releasing hormone agonists (GnRHa)
Study: 34150661
Drug: Hormone-receptor positive
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone-receptor positive breast cancer
Study: 34150661
Drug: Concerns about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concerns about chemotherapy-induced premature ovarian insufficiency and/or infertility
Study: 34150785
Drug: Reduced-intensity conditioning
Normalized name: ALLANTOIN 1 g in 100 g TOPICAL CREAM [Scar Reducer Intensive Herbal and Nutrient]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-intensity conditioning regimen with different haploidentical donors (HIDs) including fludarabine (30 mg/m2)
Study: 34151781
Drug: Acute triiodothyronine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute triiodothyronine administration
Study: 34152067
Drug: Patient-centred PEP
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient-centred PEP programme with 28-day regimen; PEP availability seven days/week, PEP hotline, out-of-facility medication delivery.
Study: 34152281
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus TB treatment support tools (TB-TSTs)
Study: 34152585
Drug: Gefapixant 50
Normalized name: Gefapixant
DrugBank: Gefapixant (DB15097)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Gefapixant 50 mg BID for 14 days
Study: 34152898
Drug: Autologous leukemic
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous leukemic apoptotic corpse-pulsed dendritic cells (DC) administered at doses of 9 × 10
Study: 34153013
Drug: Qualitative point-of-care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qualitative point-of-care drug level tests for efavirenz (EFV)
Study: 34153013
Drug: Qualitative point-of-care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qualitative point-of-care drug level tests for lopinavir (LPV)
Study: 34153013
Drug: Qualitative point-of-care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qualitative point-of-care drug level tests for dolutegravir (DTG)
Study: 34153013
Drug: Simulated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulated treatment cessation for efavirenz (EFV)
Study: 34153013
Drug: Simulated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulated treatment cessation for lopinavir (LPV)
Study: 34153013
Drug: Simulated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulated treatment cessation for dolutegravir (DTG)
Study: 34153264
Drug: ChAdOx1 nCoV-19
Normalized name: ChAdOx1 nCoV-19
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx1 nCoV-19 vaccine (two doses given 4-6 weeks apart)
Study: 34154504
Drug: Medtronic Extended
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medtronic Extended Infusion Set (EIS)
Study: 34154504
Drug: Standard 2-
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard 2- to 3-day infusion sets
Study: 34154614
Drug: Envafolimab 150
Normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Envafolimab 150 mg subcutaneously weekly in a 28-day treatment cycle
Study: 34155084
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiotherapy (SBRT) with a dose range of 30-50 Gy delivered in 1, 3, or 5 daily fractions to all sites of active metastatic disease.
Study: 34157616
Drug: Regorafenib (60-93
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regorafenib (60-93 mg/m2) administered orally once daily for 3 weeks on/1 week off; recommended phase 2 dose is 82 mg/m2.
Study: 34157782
Drug: Palbociclib plus
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib plus endocrine therapy (125 mg daily; 21 days on and 7 days off)
Study: 34157782
Drug: Palbociclib plus
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib plus endocrine therapy (Duffy null variant)
Study: 34157782
Drug: Palbociclib plus
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib plus endocrine therapy (wild-type variant)
Study: 34158124
Drug: Autologous PRP
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous PRP injection
Study: 34158124
Drug: Steroid/anesthetic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid/anesthetic injection (standard care)
Study: 34158124
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection with normal saline
Study: 34159342
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg molnupiravir
Study: 34159342
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg molnupiravir
Study: 34159343
Drug: Subcutaneous REGEN-COV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous REGEN-COV 1200mg
Study: 34159344
Drug: Subcutaneous REGEN-COV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous REGEN-COV (1200 mg)
Study: 34159577
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous anti-pseudomonal antibiotic therapy
Study: 34159577
Drug: Combination intravenous
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination intravenous anti-pseudomonal antibiotic therapy
Study: 34160684
Drug: Pembrolizumab in
Normalized name: pembrolizumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab in combination with modified FOLFOX6
Study: 34160684
Drug: Modified FOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified FOLFOX6 (reduced dose due to safety concerns)
Study: 34160752
Drug: Talazoparib 0.75
Normalized name: talazoparib 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib 0.75 mg once daily
Study: 34160752
Drug: Talazoparib 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib 1.0 mg once daily
Study: 34160752
Drug: Talazoparib (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib (both doses)
Study: 34161665
Drug: Berotralstat 150
Normalized name: berotralstat 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berotralstat 150 mg once daily
Study: 34161665
Drug: Berotralstat 110
Normalized name: berotralstat 110 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berotralstat 110 mg once daily
Study: 34162181
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus anticoagulant
Study: 34162181
Drug: Periods of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periods of thrombocytosis (>600×10^9/L)
Study: 34162264
Drug: Other CDI
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other CDI therapies
Study: 34162435
Drug: Weekly pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly pain and fatigue data collection via text messages
Study: 34163180
Drug: Mepolizumab (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab (75 mg intravenously or 100 mg subcutaneously)
Study: 34164709
Drug: Immune checkpoint
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitors (ICI) with corticosteroid treatment
Study: 34164709
Drug: Immune checkpoint
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitors (ICI) with occurrence of irAE
Study: 34164713
Drug: Tivantinib (120-360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivantinib (120-360 mg orally twice daily) + Bevacizumab (10 mg/kg intravenously every 2 weeks)
Study: 34164713
Drug: Bevacizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (10 mg/kg intravenously every 2 weeks)
Study: 34164711
Drug: L-carnitine (LC)
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-carnitine (LC) 5 mM
Study: 34164711
Drug: Acetyl-L-carnitine (ALC)
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-L-carnitine (ALC) 5 mM
Study: 34164711
Drug: Propionyl-L-carnitine (PLC)
Normalized name: glycine propionyl-L-carnitine
DrugBank: Levocarnitine propionate (DB15980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propionyl-L-carnitine (PLC) 5 mM
Study: 34164952
Drug: Rituximab (RTX)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (RTX) 375 mg/m² intravenous infusions during the initial 6-month remission-induction phase.
Study: 34164952
Drug: Rituximab (RTX)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (RTX) 375 mg/m² intravenous infusions.
Study: 34166589
Drug: Adjunctive Mood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive Mood Stabilizers
Study: 34166627
Drug: Savolitinib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Savolitinib 600 mg (bodyweight ≥50 kg) or 400 mg (bodyweight <50 kg) once daily until disease progression or intolerable toxicity.
Study: 34166998
Drug: Higher plerixafor
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher plerixafor dosing
Study: 34168015
Drug: sequential α-/β-emitter
Approvals — FDA: no, EMA: no, PMDA: no
Description: sequential α-/β-emitter therapy
Study: 34168480
Drug: First-generation EGFR-TKIs
Normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-generation EGFR-TKIs combined with chemotherapy
Study: 34168987
Drug: Pomalidomide (POM)
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide (POM) 2.6 mg/m²
Study: 34169045
Drug: Walnuts, specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnuts, specific dosage and duration not available
Study: 34169045
Drug: Long-Chain Polyunsaturated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-Chain Polyunsaturated Fatty Acids, specific dosage and duration not available
Study: 34169200
Drug: Ravulizumab administered
Normalized name: ravulizumab
DrugBank: Ravulizumab (DB11580)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ravulizumab administered every 8 weeks
Study: 34169203
Drug: High-dose PF-06730512
Normalized name: Influenza, high-dose, quadrivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose PF-06730512 (intravenous) every 2 weeks for 12 weeks
Study: 34169203
Drug: Low-dose PF-06730512
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose PF-06730512 (intravenous) every 2 weeks for 12 weeks
Study: 35410894
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) at discharge
Study: 34171919
Drug: New P2Y12
Approvals — FDA: no, EMA: no, PMDA: no
Description: New P2Y12 inhibitor regimen
Study: 34172622
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (CBT) as adjunctive treatment
Study: 34173341
Drug: Third-generation EGFR-TKI
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third-generation EGFR-TKI treatment
Study: 34173811
Drug: Dalcetrapib (cholesterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalcetrapib (cholesterol ester transfer protein inhibitor)
Study: 34173969
Drug: UVA therapy
Normalized name: UVA URSI
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVA therapy for 20 min daily for 5 days
Study: 34174177
Drug: Molecularly specific
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecularly specific positron emission tomography imaging agents targeting ACE2
Study: 34174903
Drug: Diaphragmatic Thickening
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diaphragmatic Thickening Fraction (DTF) measured at baseline and at 1, 4, 12, 24, 48, 72, and 96 hours of NIV treatment.
Study: 34174903
Drug: Respiratory rate/DTF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respiratory rate/DTF ratio measured at baseline and at 1, 4, 12, 24, 48, 72, and 96 hours of NIV treatment.
Study: 34175021
Drug: Ciltacabtagene autoleucel
Normalized name: ciltacabtagene autoleucel
DrugBank: Ciltacabtagene autoleucel (DB16738)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciltacabtagene autoleucel (cilta-cel) infusion at a target dose of 0.75 × 10^6 cells/kg
Study: 34175043
Drug: Adeno-associated virus-vectorized
Normalized name: Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2
DrugBank: Voretigene neparvovec (DB13932)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adeno-associated virus-vectorized gene therapies (gene replacement or antisense oligonucleotide-mediated pre-mRNA splicing modulation)
Study: 34175043
Drug: Experimental therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental therapies using somatic cell gene editing
Study: 34175582
Drug: Intramuscular magnesium
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular magnesium sulphate administered by community-based health workers (CHWs)
Study: 34175582
Drug: Oral methyldopa
Normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methyldopa administered by Community Health Extension Workers (CHEWs) and nurses
Study: 34176021
Drug: Dose reduction
Normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose reduction or delay due to neuropathy (group 2)
Study: 34176021
Drug: Discontinuation due
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation due to neuropathy (group 3)
Study: 34176021
Drug: Completed treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Completed treatment without alteration (group 1)
Study: 34176021
Drug: Clinician-assessed neuropathy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician-assessed neuropathy severity at dose reduction or delay
Study: 34176021
Drug: Patient-reported neuropathy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-reported neuropathy severity at cycle 4 for dose reduction or delay
Study: 34176752
Drug: Treatment adherence
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment adherence and overall survival
Study: 34177581
Drug: Lithium Carbonate;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium Carbonate; dosage and duration not available
Study: 34177626
Drug: Nasal High
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal High Flow (NHF) at 25 L/min
Study: 34178122
Drug: Subsequent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent chemotherapy (147 patients, 73.5%)
Study: 34178122
Drug: Subsequent endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent endocrine therapy (53 patients, 26.5%)
Study: 34178122
Drug: Subsequent therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent therapies after palbociclib
Study: 34180037
Drug: Idasanutlin (QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idasanutlin (QD dosing)
Study: 34180161
Drug: Overall ADHD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall ADHD medications
Study: 34181697
Drug: High levels
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High levels of fecal IgA antibodies against Cryptosporidium Cp23 sporozoite protein at one year of life
Study: 34181872
Drug: Antibody features
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody features towards VAR2CSA identified through machine learning techniques
Study: 34182032
Drug: Heparin-bonded stent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-bonded stent grafts
Study: 34183020
Drug: Regular use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular use of omega-3 fatty acid supplements (n=856)
Study: 34183020
Drug: Non-users of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-users of omega-3 fatty acid supplements (n=348)
Study: 34184326
Drug: Samples from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Samples from patients with concurrent de novo HLA DSAs
Study: 34184441
Drug: Fimasartan-based antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan-based antihypertensive therapy
Study: 34185020
Drug: Interprofessional medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interprofessional medication adherence program (IMAP) with regular motivational interviewing sessions and delivery of PKIs in electronic monitors
Study: 34185020
Drug: Interprofessional medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interprofessional medication adherence program (IMAP)
Study: 34185020
Drug: PKI pharmacokinetics
Normalized name: PKI-179
DrugBank: PKI-179 (DB13109)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PKI pharmacokinetics
Study: 34185020
Drug: PKI dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PKI dosage adaptation
Study: 34185084
Drug: Standard-care medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-care medications (triptans or over-the-counter medications)
Study: 34185953
Drug: Blinatumomab (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinatumomab (9 μg/day for week 1, 28 μg/day for weeks 2-4, followed by 2 weeks of no treatment; 28 μg/day in subsequent cycles)
Study: 34186262
Drug: Total bilirubin
Normalized name: bilirubin preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total bilirubin ≥1.93 mg/dL
Study: 34187401
Drug: Copanlisib (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copanlisib (60 mg intravenous on days 1, 8, 15 for 6 cycles of 28 days) and Rituximab (375 mg/m2)
Study: 34187831
Drug: Activities of
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activities of Daily Living (ADL) measured by modified Rankin Scale scores
Study: 34187871
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (EVT) with concurrent intravenous (IV) alteplase